Industries & Services
Pharmaceuticals & Biotechnology
Concept Studies
Market Entry Facility RX83
Client: GlaxoSmithKline
Location: Wavre, Belgium
Completion: 2001
Scope of Work: Concept, Basic and Extended Basic Engineering
Project Value: £29.0 million
CONTACT
AK pharmaceuticals (Europe)
+44 (0)1489 614422
Aker Kvaerner Pharmaceuticals (Americas)
+1 908 429 9100
Features
Bulk bacterial vaccines production facility
Two production suites with centralised services
Biosafety containment level BL3 for live areas
Flexible processing areas allowing rapid equipment changeover
Campaign production for different products
GMP compliance with EU and US FDA requirements
Clean room classifications to EU grades B, C and D
Integrated with off-plot Energy Centre for building utilities supply
Utilities floor incorporating kill tanks, clean utilities and building services
Future expansion building bay incorporated for scaled up process
Mezzanine level for HVAC systems above production level
Plant wide SCADA and materials tracking systems
Printable version
Sitemap
©
Aker Solutions
Terms of Use